Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

Qingxin Mu, Forrest M Kievit, Rajeev J. Kant, Guanyou Lin, Mike Jeon, Miqin Zhang

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Nanoparticles (NPs) for targeted therapy are required to have appropriate size, stability, drug loading and release profiles, and efficient targeting ligands. However, many of the existing NPs such as albumin, liposomes, polymers, gold NPs, etc. encounter size limit, toxicity and stability issues when loaded with drugs, fluorophores, and targeting ligands. Furthermore, antibodies are bulky and this can greatly affect the physicochemical properties of the NPs, whereas many small molecule-based targeting ligands lack specificity. Here, we report the utilization of biocompatible, biodegradable, small (∼30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand. We demonstrate the uniform size and high stability of these NPs in biological medium, their effective tumour targeting in live mice, as well as their efficient cellular targeting and selective killing in human HER2/neu-positive breast cancer cells.

Original languageEnglish (US)
Pages (from-to)18010-18014
Number of pages5
JournalNanoscale
Volume7
Issue number43
DOIs
StatePublished - Nov 21 2015
Externally publishedYes

Fingerprint

Paclitaxel
Iron oxides
Peptides
Cells
Nanoparticles
Ligands
Fluorophores
Liposomes
Antibodies
Gold
Pharmaceutical Preparations
Toxicity
ferric oxide
Tumors
Albumins
Polymers
Molecules

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. / Mu, Qingxin; Kievit, Forrest M; Kant, Rajeev J.; Lin, Guanyou; Jeon, Mike; Zhang, Miqin.

In: Nanoscale, Vol. 7, No. 43, 21.11.2015, p. 18010-18014.

Research output: Contribution to journalArticle

Mu, Qingxin ; Kievit, Forrest M ; Kant, Rajeev J. ; Lin, Guanyou ; Jeon, Mike ; Zhang, Miqin. / Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. In: Nanoscale. 2015 ; Vol. 7, No. 43. pp. 18010-18014.
@article{cad4f07a2d6f45be836d1fbc12dc767d,
title = "Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells",
abstract = "Nanoparticles (NPs) for targeted therapy are required to have appropriate size, stability, drug loading and release profiles, and efficient targeting ligands. However, many of the existing NPs such as albumin, liposomes, polymers, gold NPs, etc. encounter size limit, toxicity and stability issues when loaded with drugs, fluorophores, and targeting ligands. Furthermore, antibodies are bulky and this can greatly affect the physicochemical properties of the NPs, whereas many small molecule-based targeting ligands lack specificity. Here, we report the utilization of biocompatible, biodegradable, small (∼30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand. We demonstrate the uniform size and high stability of these NPs in biological medium, their effective tumour targeting in live mice, as well as their efficient cellular targeting and selective killing in human HER2/neu-positive breast cancer cells.",
author = "Qingxin Mu and Kievit, {Forrest M} and Kant, {Rajeev J.} and Guanyou Lin and Mike Jeon and Miqin Zhang",
year = "2015",
month = "11",
day = "21",
doi = "10.1039/c5nr04867b",
language = "English (US)",
volume = "7",
pages = "18010--18014",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "43",

}

TY - JOUR

T1 - Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

AU - Mu, Qingxin

AU - Kievit, Forrest M

AU - Kant, Rajeev J.

AU - Lin, Guanyou

AU - Jeon, Mike

AU - Zhang, Miqin

PY - 2015/11/21

Y1 - 2015/11/21

N2 - Nanoparticles (NPs) for targeted therapy are required to have appropriate size, stability, drug loading and release profiles, and efficient targeting ligands. However, many of the existing NPs such as albumin, liposomes, polymers, gold NPs, etc. encounter size limit, toxicity and stability issues when loaded with drugs, fluorophores, and targeting ligands. Furthermore, antibodies are bulky and this can greatly affect the physicochemical properties of the NPs, whereas many small molecule-based targeting ligands lack specificity. Here, we report the utilization of biocompatible, biodegradable, small (∼30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand. We demonstrate the uniform size and high stability of these NPs in biological medium, their effective tumour targeting in live mice, as well as their efficient cellular targeting and selective killing in human HER2/neu-positive breast cancer cells.

AB - Nanoparticles (NPs) for targeted therapy are required to have appropriate size, stability, drug loading and release profiles, and efficient targeting ligands. However, many of the existing NPs such as albumin, liposomes, polymers, gold NPs, etc. encounter size limit, toxicity and stability issues when loaded with drugs, fluorophores, and targeting ligands. Furthermore, antibodies are bulky and this can greatly affect the physicochemical properties of the NPs, whereas many small molecule-based targeting ligands lack specificity. Here, we report the utilization of biocompatible, biodegradable, small (∼30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand. We demonstrate the uniform size and high stability of these NPs in biological medium, their effective tumour targeting in live mice, as well as their efficient cellular targeting and selective killing in human HER2/neu-positive breast cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84946103243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946103243&partnerID=8YFLogxK

U2 - 10.1039/c5nr04867b

DO - 10.1039/c5nr04867b

M3 - Article

VL - 7

SP - 18010

EP - 18014

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 43

ER -